Compare Enact Holdings Inc (ACT) vs GeneDx Holdings Corp (WGS) Price & Performance

ACT trades at $48.43, down 1.3% on the day, near the analyst consensus price target of $49.00. The stock shows a mixed technical picture with a bullish moving average signal but neutral oscillators, while key support sits at $48. Fundamentally, the company reported strong Q2 2026 earnings of $1.26 per share, beating estimates, and maintains a robust net income margin above 54%. Recent news highlights business activity, including a dividend declaration and acquisition advisory work.

The outlook is cautiously positive, supported by earnings beats and high profitability, but risks include potential earnings volatility and negative net cash flow trends. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited near-term upside from the current price. The stock presents a value opportunity given its reasonable P/E ratio, though investors should weigh execution consistency against macroeconomic headwinds.

GeneDx Holdings Corp (WGS) trades at $84.81, down 1.77% on the day, with a bullish technical signal from moving averages and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $0.01 versus a projected loss, and revenue reached $114.4 million, driven by record testing volumes. However, the company remains unprofitable with a net income margin of -23.4% in 2026, and faces class action lawsuits filed in August 2026 alleging securities violations.

The outlook is mixed: bullish analyst consensus (90.9% buy ratings) and a return to adjusted profitability ahead of schedule support upside potential, but persistent losses, high valuation multiples like EV/EBITDA of 161.17, and legal risks pose significant challenges. Investors should weigh growth prospects in genomic testing against financial sustainability and litigation overhangs.